Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

TAILORx: Clinical Data Add Value to Recurrence Score

Publish date:: July 4, 2019

Key clinical point: Clinical risk stratification adds prognostic value to the 21-gene RS in early breast cancer.

Major finding: Among women over age 50 years, the hazard ratios for distant recurrence ranged from 2.20 to 2.36.

Study details: A secondary analysis of data from 9,427 patients from the TAILORx trial.

Disclosures: TAILORx was funded by the National Institutes of Health. Dr. Sparano reported stock ownership, a consulting role, and research funding from several pharmaceutical companies. Dr. Stearns reported consulting or advisory roles with Iridium Therapeutics; research funding from Abbvie, Biocept, MedImmune, Novartis, Pfizer, and Puma Biotechnology; and an “other relationship” with Immunomedics.

Citation:

Sparano JA et al. ASCO 2019. Abstract 503.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,